Sang Hyuck Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sang Hyuck Lee has a total of 753 co-authors. Here are the top co-authors by number of shared publications:
- Gerome Breen
Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London
28 shared publications - Charles Curtis
Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
18 shared publications - Jonathan Richard Iain Coleman
King's College London
18 shared publications - Thalia Catherine Eley
Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
15 shared publications - Abigail R. ter Kuile
Department of Clinical, Educational, and Health Psychology, University College London, London, UK
11 shared publications - Christopher Hübel
Social, Genetic & Developmental Psychiatry Centre Institute of Psychiatry, Psychology & Neuroscience, King's College London London UK
11 shared publications
Latest Publications
- Open Access
Genetic architecture and polygenic prediction of self-reported response to selective serotonin reuptake inhibitors in individuals with depression: a genome-wide meta-analysis
Selective serotonin reuptake inhibitors (SSRIs) are first-line treatments for depression, but response is highly variable, and no robust genetic predictors have been identified. We conducted a genome-wide association meta-analysis of self-reported SSRI response in 62,879 individuals of European ancestry with depression (72.6% responders) across six cohorts (seven datasets), followed by gene-set, transcriptomic, proteomic, drug-target and polygenic score (PGS) analyses. SNP-based heritability was modest but significant (h² = 3.1%, SE = 1.4%) with no genome-wide significant variants detected. Gene-set analyses implicated gamma-aminobutyric acid (GABA)ergic and glutamatergic neurotransmission, and a gene involved in glutamate transport ( SLC17A6 ) showed consistent sub-threshold evidence across pathway, transcriptomic and proteomic analyses. Drug-target enrichment for hypnotics, anxiolytics and general anesthetics further supported the GABAergic signal. A leave-one-out PGS from the discovery meta-analysis was associated with self-reported SSRI response in independent cohorts (meta-analysis OR=1.05, 95% CI 1.02–1.08, p=0.002). Higher PGS for depression, attention-deficit/hyperactivity disorder (ADHD), anxiety, post-traumatic stress disorder (PTSD), autism, addiction and schizophrenia were associated with lower odds of reported SSRI response, with ADHD, PTSD, autism and addiction remaining after adjustment for depression PGS. In contrast, educational attainment PGS was associated with better SSRI response. Self-reported SSRI response captures genetic insights relevant to antidepressant response, implicating GABAergic and glutamatergic neurotransmission. Individuals with higher genetic loading for psychiatric conditions report poorer response, and higher genetic loading for educational attainment PGS a better reported response. Although larger studies are needed to identify specific variants, self-report offers a practical, patient-centered and scalable route to collect the larger samples required.
Open AccessGenetic architecture and polygenic prediction of self-reported response to selective serotonin reuptake inhibitors in individuals with depression: a genome-wide meta-analysis
Selective serotonin reuptake inhibitors (SSRIs) are first-line treatments for depression, but response is highly variable, and no robust genetic predictors have been identified. We conducted a genome-wide association meta-analysis of self-reported SSRI response in 62,879 individuals of European ancestry with depression (72.6% responders) across six cohorts (seven datasets), followed by gene-set, transcriptomic, proteomic, drug-target and polygenic score (PGS) analyses. SNP-based heritability was modest but significant (h² = 3.1%, SE = 1.4%) with no genome-wide significant variants detected. Gene-set analyses implicated gamma-aminobutyric acid (GABA)ergic and glutamatergic neurotransmission, and a gene involved in glutamate transport ( SLC17A6 ) showed consistent sub-threshold evidence across pathway, transcriptomic and proteomic analyses. Drug-target enrichment for hypnotics, anxiolytics and general anesthetics further supported the GABAergic signal. A leave-one-out PGS from the discovery meta-analysis was associated with self-reported SSRI response in independent cohorts (meta-analysis OR=1.05, 95% CI 1.02–1.08, p=0.002). Higher PGS for depression, attention-deficit/hyperactivity disorder (ADHD), anxiety, post-traumatic stress disorder (PTSD), autism, addiction and schizophrenia were associated with lower odds of reported SSRI response, with ADHD, PTSD, autism and addiction remaining after adjustment for depression PGS. In contrast, educational attainment PGS was associated with better SSRI response. Self-reported SSRI response captures genetic insights relevant to antidepressant response, implicating GABAergic and glutamatergic neurotransmission. Individuals with higher genetic loading for psychiatric conditions report poorer response, and higher genetic loading for educational attainment PGS a better reported response. Although larger studies are needed to identify specific variants, self-report offers a practical, patient-centered and scalable route to collect the larger samples required.
- Open Access
- 19 August 2026
- Published by Springer Nature in Nature Mental Health
- Vol. 4 (9) , 1361-1377
Genomic meta-analyses of binge-eating behavior and anorexia nervosa yield insights into the unique and shared biology of eating disorder phenotypes
Eating disorders—including anorexia nervosa (AN), bulimia nervosa and binge-eating disorder—are clinically distinct but exhibit symptom overlap and diagnostic crossover. Genomic analyses have mostly examined AN. Here we conducted a genomic meta-analysis of case–control studies of binge-eating behavior (BE; 39,279 cases, 1,227,436 controls), alongside analyses of AN (24,223 cases, 1,243,971 controls) and its subtypes (all European ancestries). We identified six BE-associated loci, including loci associated with a higher body mass index and impulse-control behaviors. AN genome-wide association studies yielded eight loci, validating six loci. Subsequent polygenic risk score analysis demonstrated an association with AN in two East Asian ancestry studies. BE and AN exhibited similar positive genetic correlations with psychiatric disorders but opposing genetic correlations with anthropometric traits. Most of the genetic signal in BE and AN was not shared with body mass index. We have extended eating disorder genomics beyond AN; future work will incorporate multiple diagnoses and global ancestries.
- 19 August 2026
- Published by Springer Nature in Nature Mental Health
- Vol. 4 (9) , 1361-1377
Open AccessGenomic meta-analyses of binge-eating behavior and anorexia nervosa yield insights into the unique and shared biology of eating disorder phenotypes
Eating disorders—including anorexia nervosa (AN), bulimia nervosa and binge-eating disorder—are clinically distinct but exhibit symptom overlap and diagnostic crossover. Genomic analyses have mostly examined AN. Here we conducted a genomic meta-analysis of case–control studies of binge-eating behavior (BE; 39,279 cases, 1,227,436 controls), alongside analyses of AN (24,223 cases, 1,243,971 controls) and its subtypes (all European ancestries). We identified six BE-associated loci, including loci associated with a higher body mass index and impulse-control behaviors. AN genome-wide association studies yielded eight loci, validating six loci. Subsequent polygenic risk score analysis demonstrated an association with AN in two East Asian ancestry studies. BE and AN exhibited similar positive genetic correlations with psychiatric disorders but opposing genetic correlations with anthropometric traits. Most of the genetic signal in BE and AN was not shared with body mass index. We have extended eating disorder genomics beyond AN; future work will incorporate multiple diagnoses and global ancestries.
- Open Access
- 29 June 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (11) , 6224-6237
Genome-wide genetic overlap between fear-based disorders and generalised anxiety disorder
Twin studies reveal high genetic overlap between anxiety disorders and depression, contributing to the internalising spectrum. Some genetic specificity for fear-based anxiety disorders (fear), distinct from general anxiety and depression (distress), has also emerged. Limited datasets with detailed phenotyping across anxiety disorders have restricted most genome-wide association studies (GWAS) to “any anxiety diagnosis”. Additional genome-wide evidence to discern genetic differences between fear and distress is required. We conducted GWAS meta-analyses of fear (panic, agoraphobia, specific phobia, social anxiety disorder) and generalised anxiety disorder (GAD), measured using brief single-item and detailed symptom-based diagnoses from three datasets. We explored two control group criteria: phenotype-specific (fear/GAD) or broader anxiety/depression screening. We identified one independent genome-wide significant locus and three gene-level associations with fear (up to 35,523 N cases ; 157,447 N controls ). Four genome-wide significant loci and three gene-level associations were identified for GAD (up to 60,879 N cases ; 117,064 N controls ). The genetic correlation between fear and GAD was significantly different from unity only when excluding a depression-enriched dataset and using phenotype-specific control screening (r g = 0.87; P = 9.32 × 10 −3 ). Most complex traits had statistically similar genetic correlations with fear and GAD, including depression. Exceptions included general cognitive ability, educational attainment, and coronary artery disease, showing statistically stronger genetic correlations with fear than GAD, while bipolar disorder type I, anorexia nervosa, and neuroticism displayed the opposite pattern. Our findings partially support a distress-fear genetic distinction, but show stronger evidence for an overarching genetic liability to internalising psychopathology driving comorbidity across anxiety disorders and depression.
- 29 June 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (11) , 6224-6237
Open AccessGenome-wide genetic overlap between fear-based disorders and generalised anxiety disorder
Twin studies reveal high genetic overlap between anxiety disorders and depression, contributing to the internalising spectrum. Some genetic specificity for fear-based anxiety disorders (fear), distinct from general anxiety and depression (distress), has also emerged. Limited datasets with detailed phenotyping across anxiety disorders have restricted most genome-wide association studies (GWAS) to “any anxiety diagnosis”. Additional genome-wide evidence to discern genetic differences between fear and distress is required. We conducted GWAS meta-analyses of fear (panic, agoraphobia, specific phobia, social anxiety disorder) and generalised anxiety disorder (GAD), measured using brief single-item and detailed symptom-based diagnoses from three datasets. We explored two control group criteria: phenotype-specific (fear/GAD) or broader anxiety/depression screening. We identified one independent genome-wide significant locus and three gene-level associations with fear (up to 35,523 N cases ; 157,447 N controls ). Four genome-wide significant loci and three gene-level associations were identified for GAD (up to 60,879 N cases ; 117,064 N controls ). The genetic correlation between fear and GAD was significantly different from unity only when excluding a depression-enriched dataset and using phenotype-specific control screening (r g = 0.87; P = 9.32 × 10 −3 ). Most complex traits had statistically similar genetic correlations with fear and GAD, including depression. Exceptions included general cognitive ability, educational attainment, and coronary artery disease, showing statistically stronger genetic correlations with fear than GAD, while bipolar disorder type I, anorexia nervosa, and neuroticism displayed the opposite pattern. Our findings partially support a distress-fear genetic distinction, but show stronger evidence for an overarching genetic liability to internalising psychopathology driving comorbidity across anxiety disorders and depression.
- Open Access
Genome-wide genetic overlap between fear-based disorders and generalised anxiety disorder
Twin studies reveal high genetic overlap between anxiety disorders and depression, contributing to the internalising spectrum. Some genetic specificity for fear-based anxiety disorders (fear), distinct from general anxiety and depression (distress), has also emerged. Limited datasets with detailed phenotyping across anxiety disorders have restricted most genome-wide association studies (GWAS) to “any anxiety diagnosis”. Additional genome-wide evidence to discern genetic differences between fear and distress is required. We conducted GWAS meta-analyses of fear (panic, agoraphobia, specific phobia, social anxiety disorder) and generalised anxiety disorder (GAD), measured using brief single-item and detailed symptom-based diagnoses from three datasets. We explored two control group criteria: phenotype-specific (fear/GAD) or broader anxiety/depression screening. We identified one SNP-based independent locus and three gene-level genome-wide significant (GWS) associations with fear (up to 35,523 N cases ; 157,447 N controls ). Four GWS SNP-based loci and three gene-level loci were associated with GAD (up to 60,879 N cases ; 117,064 N controls ). The genetic correlation between fear and GAD was significantly different from unity only when excluding a depression-enriched dataset and using phenotype-specific control screening (r g = 0.87; P = 9.32 × 10 −3 ). Most complex traits had statistically similar genetic correlations with fear and GAD, including depression. Exceptions included general cognitive ability, educational attainment, and coronary artery disease, showing statistically stronger genetic correlations with fear than GAD, while bipolar disorder type I, anorexia nervosa, and neuroticism displayed the opposite pattern. Our findings partially support a distress-fear genetic distinction, but show stronger evidence for an overarching genetic liability to internalising psychopathology driving comorbidity across anxiety disorders and depression.
Open AccessGenome-wide genetic overlap between fear-based disorders and generalised anxiety disorder
Twin studies reveal high genetic overlap between anxiety disorders and depression, contributing to the internalising spectrum. Some genetic specificity for fear-based anxiety disorders (fear), distinct from general anxiety and depression (distress), has also emerged. Limited datasets with detailed phenotyping across anxiety disorders have restricted most genome-wide association studies (GWAS) to “any anxiety diagnosis”. Additional genome-wide evidence to discern genetic differences between fear and distress is required. We conducted GWAS meta-analyses of fear (panic, agoraphobia, specific phobia, social anxiety disorder) and generalised anxiety disorder (GAD), measured using brief single-item and detailed symptom-based diagnoses from three datasets. We explored two control group criteria: phenotype-specific (fear/GAD) or broader anxiety/depression screening. We identified one SNP-based independent locus and three gene-level genome-wide significant (GWS) associations with fear (up to 35,523 N cases ; 157,447 N controls ). Four GWS SNP-based loci and three gene-level loci were associated with GAD (up to 60,879 N cases ; 117,064 N controls ). The genetic correlation between fear and GAD was significantly different from unity only when excluding a depression-enriched dataset and using phenotype-specific control screening (r g = 0.87; P = 9.32 × 10 −3 ). Most complex traits had statistically similar genetic correlations with fear and GAD, including depression. Exceptions included general cognitive ability, educational attainment, and coronary artery disease, showing statistically stronger genetic correlations with fear than GAD, while bipolar disorder type I, anorexia nervosa, and neuroticism displayed the opposite pattern. Our findings partially support a distress-fear genetic distinction, but show stronger evidence for an overarching genetic liability to internalising psychopathology driving comorbidity across anxiety disorders and depression.
- Open Access
Disentangling Perinatal Depression from General Major Depression: A GWAS Meta-Analysis and Genetic Correlation Approach in European Datasets
Perinatal depression (PND), defined as depression occurring during the perinatal period, has a higher heritability than general major depressive disorder (MDD) yet remains understudied. This study aimed to increase power in PND GWAS and explore its genetic architecture. We meta-analysed an existing study by the Psychiatric Genomics Consortium (PGC) with data from the GLAD+ study and UK Biobank (UKB), yielding 25,452 PND cases and 72,131 controls. Linkage disequilibrium score (LDSC) regression was used to compare genetic correlation profiles of PND and general MDD across traits. Gene, gene-set, and tissue expression analyses were also performed. The genetic correlation between PGC PND and UKB-GLAD+ PND was high (0.93). No genome-wide significant loci emerged from the meta-analysis. The SNP-based heritability of PND on the liability scale was 0.089. PND and MDD displayed broadly similar genetic correlation patterns. Still, PND had a significantly higher genetic correlation with anxiety disorders, while MDD showed higher correlations with cannabis use disorder, bipolar disorder, and ADHD. Tissue expression analysis showed the highest enrichment in brain regions like the cortex and nucleus accumbens. The sample size was not large enough to detect genome-wide significant loci, and further analyses in ancestrally diverse datasets are needed. PND definitions were heterogeneous, and precise information on onset timing across studies was lacking. This study, the largest European ancestry meta-analysis of PND to date, suggests distinct genetic factors may differentiate PND from MDD in general. The findings highlight the need for larger and more ancestrally diverse studies to identify genome-wide significant loci.
Open AccessDisentangling Perinatal Depression from General Major Depression: A GWAS Meta-Analysis and Genetic Correlation Approach in European Datasets
Perinatal depression (PND), defined as depression occurring during the perinatal period, has a higher heritability than general major depressive disorder (MDD) yet remains understudied. This study aimed to increase power in PND GWAS and explore its genetic architecture. We meta-analysed an existing study by the Psychiatric Genomics Consortium (PGC) with data from the GLAD+ study and UK Biobank (UKB), yielding 25,452 PND cases and 72,131 controls. Linkage disequilibrium score (LDSC) regression was used to compare genetic correlation profiles of PND and general MDD across traits. Gene, gene-set, and tissue expression analyses were also performed. The genetic correlation between PGC PND and UKB-GLAD+ PND was high (0.93). No genome-wide significant loci emerged from the meta-analysis. The SNP-based heritability of PND on the liability scale was 0.089. PND and MDD displayed broadly similar genetic correlation patterns. Still, PND had a significantly higher genetic correlation with anxiety disorders, while MDD showed higher correlations with cannabis use disorder, bipolar disorder, and ADHD. Tissue expression analysis showed the highest enrichment in brain regions like the cortex and nucleus accumbens. The sample size was not large enough to detect genome-wide significant loci, and further analyses in ancestrally diverse datasets are needed. PND definitions were heterogeneous, and precise information on onset timing across studies was lacking. This study, the largest European ancestry meta-analysis of PND to date, suggests distinct genetic factors may differentiate PND from MDD in general. The findings highlight the need for larger and more ancestrally diverse studies to identify genome-wide significant loci.
- Open Access
Combined family history and polygenic score prediction of major depressive disorder
Importance: Major depressive disorder (MDD) is a complex psychiatric disorder influenced by genetic, social, and environmental factors. Family history, genome-wide polygenic scores, and childhood trauma are key predictors of MDD onset with distinct contributions. Objective: This study modelled the combined effects of family history of multiple psychiatric disorders, polygenic scores of multiple traits, and childhood trauma, alongside sociodemographic factors on MDD diagnosis and number of episodes. We aimed to build and externally validate predictive models for MDD risk and severity. Participants: We used data from the Genetic Links to Anxiety and Depression Study and other NIHR BioResource studies (GLAD+) and UK Biobank (UKB) collected between 2016 and 2023. Outcomes and measurements: MDD diagnosis followed DSM-5 criteria using online questionnaire data. Family history (Yes/No) was reported for up to 22 psychiatric disorders. Polygenic scores were calculated based on genome-wide association studies (n=22). Participants answered the five-item childhood trauma screener. We used elastic net regression with nested cross-validation to select the best predictors. Results: In GLAD+ (9,927 MDD cases, 4,452 controls), family history explained 17% of the MDD variance, followed by childhood trauma (11%), sociodemographics (10%), and polygenic scores (7%), resulting in 33% of the MDD variance (AUC-ROC=0.84). In UKB (40,667 MDD cases, 70,755 controls), family history explained 13% of the MDD variance, childhood trauma (7%), sociodemographics (6%), and polygenic scores (4%). Combined together, the predictors explained 23% of the variance (AUC-ROC=0.74). The top five individual predictors were family history of depression, childhood trauma, female sex, family history of anxiety, and the MDD polygenic score in both cohorts. The predictive models were externally well-validated across GLAD+ and UKB obtaining comparable predictive performance. Finally, when combined, the predictors explained 26% and 12% of the variance in the number of MDD episodes in GLAD+ and UKB respectively. Conclusions: Integrating family history, PRSs, ChT, and sociodemographic factors can predict risk of an MDD diagnosis and its recurrent course. This model may help identify individuals at high risk for depression in clinical settings, assess its severity, enable early diagnosis and potentially personalize treatment.
Open AccessCombined family history and polygenic score prediction of major depressive disorder
Importance: Major depressive disorder (MDD) is a complex psychiatric disorder influenced by genetic, social, and environmental factors. Family history, genome-wide polygenic scores, and childhood trauma are key predictors of MDD onset with distinct contributions. Objective: This study modelled the combined effects of family history of multiple psychiatric disorders, polygenic scores of multiple traits, and childhood trauma, alongside sociodemographic factors on MDD diagnosis and number of episodes. We aimed to build and externally validate predictive models for MDD risk and severity. Participants: We used data from the Genetic Links to Anxiety and Depression Study and other NIHR BioResource studies (GLAD+) and UK Biobank (UKB) collected between 2016 and 2023. Outcomes and measurements: MDD diagnosis followed DSM-5 criteria using online questionnaire data. Family history (Yes/No) was reported for up to 22 psychiatric disorders. Polygenic scores were calculated based on genome-wide association studies (n=22). Participants answered the five-item childhood trauma screener. We used elastic net regression with nested cross-validation to select the best predictors. Results: In GLAD+ (9,927 MDD cases, 4,452 controls), family history explained 17% of the MDD variance, followed by childhood trauma (11%), sociodemographics (10%), and polygenic scores (7%), resulting in 33% of the MDD variance (AUC-ROC=0.84). In UKB (40,667 MDD cases, 70,755 controls), family history explained 13% of the MDD variance, childhood trauma (7%), sociodemographics (6%), and polygenic scores (4%). Combined together, the predictors explained 23% of the variance (AUC-ROC=0.74). The top five individual predictors were family history of depression, childhood trauma, female sex, family history of anxiety, and the MDD polygenic score in both cohorts. The predictive models were externally well-validated across GLAD+ and UKB obtaining comparable predictive performance. Finally, when combined, the predictors explained 26% and 12% of the variance in the number of MDD episodes in GLAD+ and UKB respectively. Conclusions: Integrating family history, PRSs, ChT, and sociodemographic factors can predict risk of an MDD diagnosis and its recurrent course. This model may help identify individuals at high risk for depression in clinical settings, assess its severity, enable early diagnosis and potentially personalize treatment.
- Open Access
- 5 August 2025
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 55, e224
Genetic overlap between functional impairment and depression and anxiety symptom severity: evidence from the GLAD Study
Background: Functional impairment in daily activities, such as work and socializing, is part of the diagnostic criteria for major depressive disorder and most anxiety disorders. Despite evidence that symptom severity and functional impairment are partially distinct, functional impairment is often overlooked. To assess whether functional impairment captures diagnostically relevant genetic liability beyond that of symptoms, we aimed to estimate the heritability of, and genetic correlations between, key measures of current depression symptoms, anxiety symptoms, and functional impairment. Methods: In 17,130 individuals with lifetime depression or anxiety from the Genetic Links to Anxiety and Depression (GLAD) Study, we analyzed total scores from the Patient Health Questionnaire-9 (depression symptoms), Generalized Anxiety Disorder-7 (anxiety symptoms), and Work and Social Adjustment Scale (functional impairment). Genome-wide association analyses were performed with REGENIE. Heritability was estimated using GCTA-GREML and genetic correlations with bivariate-GREML. Results: The phenotypic correlations were moderate across the three measures (Pearson’s r = 0.50–0.69). All three scales were found to be under low but significant genetic influence (single-nucleotide polymorphism-based heritability [h2SNP] = 0.11–0.19) with high genetic correlations between them (rg = 0.79–0.87). Conclusions: Among individuals with lifetime depression or anxiety from the GLAD Study, the genetic variants that underlie symptom severity largely overlap with those influencing functional impairment. This suggests that self-reported functional impairment, while clinically relevant for diagnosis and treatment outcomes, does not reflect substantial additional genetic liability beyond that captured by symptom-based measures of depression or anxiety.
- 5 August 2025
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 55, e224
Open AccessGenetic overlap between functional impairment and depression and anxiety symptom severity: evidence from the GLAD Study
Background: Functional impairment in daily activities, such as work and socializing, is part of the diagnostic criteria for major depressive disorder and most anxiety disorders. Despite evidence that symptom severity and functional impairment are partially distinct, functional impairment is often overlooked. To assess whether functional impairment captures diagnostically relevant genetic liability beyond that of symptoms, we aimed to estimate the heritability of, and genetic correlations between, key measures of current depression symptoms, anxiety symptoms, and functional impairment. Methods: In 17,130 individuals with lifetime depression or anxiety from the Genetic Links to Anxiety and Depression (GLAD) Study, we analyzed total scores from the Patient Health Questionnaire-9 (depression symptoms), Generalized Anxiety Disorder-7 (anxiety symptoms), and Work and Social Adjustment Scale (functional impairment). Genome-wide association analyses were performed with REGENIE. Heritability was estimated using GCTA-GREML and genetic correlations with bivariate-GREML. Results: The phenotypic correlations were moderate across the three measures (Pearson’s r = 0.50–0.69). All three scales were found to be under low but significant genetic influence (single-nucleotide polymorphism-based heritability [h2SNP] = 0.11–0.19) with high genetic correlations between them (rg = 0.79–0.87). Conclusions: Among individuals with lifetime depression or anxiety from the GLAD Study, the genetic variants that underlie symptom severity largely overlap with those influencing functional impairment. This suggests that self-reported functional impairment, while clinically relevant for diagnosis and treatment outcomes, does not reflect substantial additional genetic liability beyond that captured by symptom-based measures of depression or anxiety.
- Open Access
- 25 July 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (9) , 110520
TET2 has endothelial-specific roles in interferon responses that are dysregulated by hyperglycemia in vitro and in vivo
- 25 July 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (9) , 110520
Open AccessTET2 has endothelial-specific roles in interferon responses that are dysregulated by hyperglycemia in vitro and in vivo
- Open Access
Genome-wide meta-analysis identifies genetic risk factors and implicates multiple body systems in panic attacks and disorder
Introductory paragraph: Panic attacks, sudden episodes of intense fear accompanied by physical and psychological symptoms, affect approximately 23% of the population 1,2 . Panic disorder, diagnosed in 2– 4% 3 , involves recurrent attacks followed by persistent worry about further attacks, leading to functional impairment and avoidance behaviours 1,2 . We conducted genome-wide association meta-analyses of panic attacks and panic disorder (61,746 and 29,775 cases, respectively, and 105,814 controls), identifying the first genome-wide significant variants for both traits (16 for panic attacks; 7 for panic disorder). Geneset analysis using single-cell RNA sequencing data implicated afferent neurons from the eye, heart, and lung in panic attacks, suggesting a critical role for sensory processing and interoceptive awareness. Further analyses suggested that these associations generalize to other psychiatric disorders. These findings offer novel insights into the biological mechanisms underlying panic, the role of afferent neurons, and may inform the development of more targeted and effective interventions.
Open AccessGenome-wide meta-analysis identifies genetic risk factors and implicates multiple body systems in panic attacks and disorder
Introductory paragraph: Panic attacks, sudden episodes of intense fear accompanied by physical and psychological symptoms, affect approximately 23% of the population 1,2 . Panic disorder, diagnosed in 2– 4% 3 , involves recurrent attacks followed by persistent worry about further attacks, leading to functional impairment and avoidance behaviours 1,2 . We conducted genome-wide association meta-analyses of panic attacks and panic disorder (61,746 and 29,775 cases, respectively, and 105,814 controls), identifying the first genome-wide significant variants for both traits (16 for panic attacks; 7 for panic disorder). Geneset analysis using single-cell RNA sequencing data implicated afferent neurons from the eye, heart, and lung in panic attacks, suggesting a critical role for sensory processing and interoceptive awareness. Further analyses suggested that these associations generalize to other psychiatric disorders. These findings offer novel insights into the biological mechanisms underlying panic, the role of afferent neurons, and may inform the development of more targeted and effective interventions.
- Open Access
- 8 May 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (10) , 4492
Investigating the Performance of Oxford Nanopore Long-Read Sequencing with Respect to Illumina Microarrays and Short-Read Sequencing
Oxford Nanopore Technologies (ONT) long-read sequencing (LRS) has emerged as a promising genomic analysis tool, yet comprehensive benchmarks with established platforms across diverse datasets remain limited. This study aimed to benchmark LRS performance against Illumina short-read sequencing (SRS) and microarrays for variant detection across different genomic contexts and to evaluate the impact of experimental factors. We sequenced 14 human genomes using the three platforms and evaluated single nucleotide variants (SNVs), insertions/deletions (indels), and structural variants (SVs) detection, stratifying by high-complexity, low-complexity, and dark genome regions while assessing effects of multiplexing, depth, and read length. LRS SNV accuracy was slightly lower than that of SRS in high-complexity regions (F-measure: 0.954 vs. 0.967) but showed comparable sensitivity in low-complexity regions. LRS showed robust performance for small (1–5 bp) indels in high-complexity regions (F-measure: 0.869), but SRS agreement decreased significantly in low-complexity regions and for larger indel sizes. Within dark regions, LRS identified more indels than SRS, but showed lower base-level accuracy. LRS identified 2.86 times more SVs than SRS, excelling at detecting large variants (>6 kb), with SV detection improving with sequencing depth. Sequencing depth strongly influenced variant calling performance, whereas multiplexing effects were minimal. Our findings provide valuable insights for optimising LRS applications in genomic research and diagnostics.
- 8 May 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (10) , 4492
Open AccessInvestigating the Performance of Oxford Nanopore Long-Read Sequencing with Respect to Illumina Microarrays and Short-Read Sequencing
Oxford Nanopore Technologies (ONT) long-read sequencing (LRS) has emerged as a promising genomic analysis tool, yet comprehensive benchmarks with established platforms across diverse datasets remain limited. This study aimed to benchmark LRS performance against Illumina short-read sequencing (SRS) and microarrays for variant detection across different genomic contexts and to evaluate the impact of experimental factors. We sequenced 14 human genomes using the three platforms and evaluated single nucleotide variants (SNVs), insertions/deletions (indels), and structural variants (SVs) detection, stratifying by high-complexity, low-complexity, and dark genome regions while assessing effects of multiplexing, depth, and read length. LRS SNV accuracy was slightly lower than that of SRS in high-complexity regions (F-measure: 0.954 vs. 0.967) but showed comparable sensitivity in low-complexity regions. LRS showed robust performance for small (1–5 bp) indels in high-complexity regions (F-measure: 0.869), but SRS agreement decreased significantly in low-complexity regions and for larger indel sizes. Within dark regions, LRS identified more indels than SRS, but showed lower base-level accuracy. LRS identified 2.86 times more SVs than SRS, excelling at detecting large variants (>6 kb), with SV detection improving with sequencing depth. Sequencing depth strongly influenced variant calling performance, whereas multiplexing effects were minimal. Our findings provide valuable insights for optimising LRS applications in genomic research and diagnostics.